Safety of nivolumab in combination with prior or concurrent radiotherapy in the treatment of hepatocellular carcinoma

Abstract

We reviewed patients who underwent RT directed to the liver before or at the same time as nivolumab for HCC. Toxicity was assessed using the Common Term Criteria for Side Effects v5.0, up to disease progression, systemic therapy changes, additional liver-directed local area therapy (LRT), or death. We compared the prevalence (PR) of patients who underwent pre- and simultaneous RT. Children-Turcotte-Pugh (CTP) and albumin-bilirubin (ALBI) scores at 1, 3, and 6 months were compared to baseline.

Results We identified 55 patients with a median follow-up of 6.0 months. 34 (62%) received the previous RT and 21 (38%) received it at the same time. Grade 3 or higher toxicity occurred in 8 patients (17%). Grade 3+ toxicity was not different between the previous RT cohort for univariate analysis and the concurrent RT cohort (OR 1.91, 95% CI: 0.42, 8.59), but in the previous RT cohort for multivariate analysis. It was high (OR 5.42, 95% CI: 1.42, 20.67). ; p = 0.013). Average CTP scores increased from baseline (6.33) at months (7.04, 95% CI: 6.80 to 7.27) and 3 months (6.81, 95% CI: 6, 43 to 7.19) and then normalized. .. The average ALBI score increased from the monthly baseline (-1.93) (-1.75; 95% CI-1.84, -1.66), with no subsequent difference.